申请人:Boehringer Ingelheim International GmbH
公开号:US20210380579A1
公开(公告)日:2021-12-09
The present invention encompasses compounds of formula (I)
wherein the groups R
1
, A, G, LK and t have the meanings given in the claims and specification, their use as degraders of SMARCA2 and/or SMARCA4, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.